Caroline Seymour

CER-1236 has received fast track designation from the FDA for the treatment of patients with acute myeloid leukemia.

Continuous zanubrutinib improved PFS and showed a trend for improved OS vs fixed-duration venetoclax-based therapy in treatment-naive CLL/SLL.

The addition of abemaciclib to endocrine therapy after surgery improved OS in patients with HR-positive, HER2-negative breast cancer with positive nodes.

Pegtarazimod has received orphan drug designation from the European Medicines Agency for the management of graft-vs-host disease.

The FDA has received a premarket approval application supported by positive results from the PANOVA-3 trial for Tumor Treating Fields (TTFields)—electric fields that exert physical forces to kill cancer cells via a variety of mechanisms—for locally advanced pancreatic cancer.

HLD-0915 has received fast track designation from the FDA, allowing for more frequent communication with the agency regarding the drug’s candidacy for approval.

Perioperative pembrolizumab has received the green light for use in combination with radiotherapy with or without cisplatin in PD-L1–positive HNSCC.

The NCCN Clinical Practice Guidelines in Oncology for SCLC added new recommendations for LEMS, the use of amifampridine, and VGCC antibody testing.

Nuvisertib has received orphan drug designation from the EMA for patients with myelofibrosis.

Ivonescimab plus chemotherapy is under review in China for the frontline treatment of patients with advanced squamous non–small cell lung cancer.

Can-Fite has reached the over 50% enrollment milestone for an ongoing phase 2a trial evaluating namodenoson in pancreatic cancer.

Sandip Patel, MD, explores how AI and multiomics are transforming localized non–small cell lung cancer care.

Ibrutinib has received an expanded indication from the European Commission for the treatment of patients with newly diagnosed MCL eligible for transplant.

ICT01 has received orphan drug designation from the FDA for the treatment of patients with acute myeloid leukemia.

ZEN-3694 has received fast track designation from the FDA for use in combination with abemaciclib for patients with previously treated NUT carcinoma.

SH-110 received orphan drug designation from the FDA for the treatment of patients with glioma.

ADRX-0405 has received orphan drug designation from the FDA for the treatment of patients with gastric cancer.

Obecabtagene autoleucel proved active and safe as treatment for patients with relapsed/refractory B-cell acute lymphoblastic leukemia regardless of age.

Revumenib’s sNDA has received priority review from the FDA for patients with relapsed or refractory NPM1-mutant acute myeloid leukemia.

The EMA’s Committee for Medicinal Products for Human Use granted a positive opinion for nirogacestat for the treatment of patients with desmoid tumors.

Atezolizumab plus bevacizumab and chemotherapy is active in patients with persistent or recurrent metastatic cervical cancer irrespective of PD-L1 CPS.

Comparable survival outcomes were seen between all 3 FDA-approved CAR T-cell therapies across indications in patients with DLBCL over a 3-year period.

CHM CDH17 has received fast track designation from the FDA for the treatment of patients with gastroenteropancreatic neuroendocrine tumors.

Time-limited therapy with acalabrutinib plus venetoclax with or without obinutuzumab is approved in the European Union for untreated patients with CLL.

The first CAR T-cell therapy designed for patients with relapsed/refractory AL amyloidosis showed feasibility and early efficacy and safety signals.

Neoadjuvant chemotherapy and nivolumab and adjuvant nivolumab prolonged EFS vs placebo in patients with resectable NSCLC in follow-up from CheckMate-77T.

Emergent ESR1-mutant, ER-positive, HER2-negative advanced breast cancer was best treated with camizestrant and continued CDK4/6 inhibition vs SOC therapy.

Durable improvements in transfusion independence and an early indication of potential OS benefit were seen with luspatercept in extended follow-up.

PFS was improved when patients with ESR1-mutant ER-positive, HER2-negative advanced breast cancer received treatment with vepdegestrant vs fulvestrant.

Nivolumab has been approved for subcutaneous use across several adult solid tumor indications that have an existing indication for intravenous use.